BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 21595927)

  • 1. HGF/c-met/Stat3 signaling during skin tumor cell invasion: indications for a positive feedback loop.
    Syed ZA; Yin W; Hughes K; Gill JN; Shi R; Clifford JL
    BMC Cancer; 2011 May; 11():180. PubMed ID: 21595927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Active Stat3 is required for survival of human squamous cell carcinoma cells in serum-free conditions.
    Yin W; Cheepala S; Roberts JN; Syson-Chan K; DiGiovanni J; Clifford JL
    Mol Cancer; 2006 Apr; 5():15. PubMed ID: 16603078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transforming growth factor-beta signaling-deficient fibroblasts enhance hepatocyte growth factor signaling in mammary carcinoma cells to promote scattering and invasion.
    Cheng N; Chytil A; Shyr Y; Joly A; Moses HL
    Mol Cancer Res; 2008 Oct; 6(10):1521-33. PubMed ID: 18922968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Boswellia frereana suppresses HGF-mediated breast cancer cell invasion and migration through inhibition of c-Met signalling.
    Parr C; Ali AY
    J Transl Med; 2018 Oct; 16(1):281. PubMed ID: 30314527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma.
    Zhao Y; Zhang J; Tian Y; Xue C; Hu Z; Zhang L
    Drug Des Devel Ther; 2015; 9():4897-907. PubMed ID: 26345996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Attenuation of MET-mediated migration and invasion in hepatocellular carcinoma cells by SOCS1.
    Gui Y; Khan MGM; Bobbala D; Dubois C; Ramanathan S; Saucier C; Ilangumaran S
    World J Gastroenterol; 2017 Sep; 23(36):6639-6649. PubMed ID: 29085209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of HGF expression by ΔEGFR-mediated c-Met activation in glioblastoma cells.
    Garnett J; Chumbalkar V; Vaillant B; Gururaj AE; Hill KS; Latha K; Yao J; Priebe W; Colman H; Elferink LA; Bogler O
    Neoplasia; 2013 Jan; 15(1):73-84. PubMed ID: 23359207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatocyte growth factor/c-Met signaling promotes the progression of experimental human neuroblastomas.
    Hecht M; Papoutsi M; Tran HD; Wilting J; Schweigerer L
    Cancer Res; 2004 Sep; 64(17):6109-18. PubMed ID: 15342394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Feed-forward activation of STAT3 signaling limits the efficacy of c-Met inhibitors in esophageal squamous cell carcinoma (ESCC) treatment.
    Zhao D; Chen J; Wang Y; Zhang L; Zhang J; Zhang W; Fan J; Li J; Zhan Q
    Mol Carcinog; 2021 Jul; 60(7):481-496. PubMed ID: 34018249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Invasiveness of hepatocellular carcinoma cell lines: contribution of hepatocyte growth factor, c-met, and transcription factor Ets-1.
    Jiang Y; Xu W; Lu J; He F; Yang X
    Biochem Biophys Res Commun; 2001 Sep; 286(5):1123-30. PubMed ID: 11527416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soluble c-Met receptors inhibit phosphorylation of c-Met and growth of hepatocyte growth factor: c-Met-dependent tumors in animal models.
    Coxon A; Rex K; Meyer S; Sun J; Sun J; Chen Q; Radinsky R; Kendall R; Burgess TL
    Mol Cancer Ther; 2009 May; 8(5):1119-25. PubMed ID: 19435874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer.
    Knowles LM; Stabile LP; Egloff AM; Rothstein ME; Thomas SM; Gubish CT; Lerner EC; Seethala RR; Suzuki S; Quesnelle KM; Morgan S; Ferris RL; Grandis JR; Siegfried JM
    Clin Cancer Res; 2009 Jun; 15(11):3740-50. PubMed ID: 19470725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effective inhibition of c-MET-mediated signaling, growth and migration of ovarian cancer cells is influenced by the ovarian tissue microenvironment.
    Kwon Y; Smith BD; Zhou Y; Kaufman MD; Godwin AK
    Oncogene; 2015 Jan; 34(2):144-53. PubMed ID: 24362531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heparin inhibits Hepatocyte Growth Factor induced motility and invasion of hepatocellular carcinoma cells through early growth response protein 1.
    Ozen E; Gozukizil A; Erdal E; Uren A; Bottaro DP; Atabey N
    PLoS One; 2012; 7(8):e42717. PubMed ID: 22912725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of hepatocyte growth factor/c-Met signaling in regulating urokinase plasminogen activator on invasiveness in human hepatocellular carcinoma: a potential therapeutic target.
    Lee KH; Choi EY; Hyun MS; Jang BI; Kim TN; Lee HJ; Eun JY; Kim HG; Yoon SS; Lee DS; Kim JH; Kim JR
    Clin Exp Metastasis; 2008; 25(1):89-96. PubMed ID: 17992475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of c-met in oral SCC promotes hepatocyte growth factor-induced disruption of cadherin junctions and invasion.
    Murai M; Shen X; Huang L; Carpenter WM; Lin CS; Silverman S; Regezi J; Kramer RH
    Int J Oncol; 2004 Oct; 25(4):831-40. PubMed ID: 15375530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HGF-mediated crosstalk between cancer-associated fibroblasts and MET-unamplified gastric cancer cells activates coordinated tumorigenesis and metastasis.
    Ding X; Ji J; Jiang J; Cai Q; Wang C; Shi M; Yu Y; Zhu Z; Zhang J
    Cell Death Dis; 2018 Aug; 9(9):867. PubMed ID: 30158543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyr61 mediates hepatocyte growth factor-dependent tumor cell growth, migration, and Akt activation.
    Goodwin CR; Lal B; Zhou X; Ho S; Xia S; Taeger A; Murray J; Laterra J
    Cancer Res; 2010 Apr; 70(7):2932-41. PubMed ID: 20233866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Matriptase is required for the active form of hepatocyte growth factor induced Met, focal adhesion kinase and protein kinase B activation on neural stem/progenitor cell motility.
    Fang JD; Lee SL
    Biochim Biophys Acta; 2014 Jul; 1843(7):1285-94. PubMed ID: 24685580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activated MET is a molecular prognosticator and potential therapeutic target for malignant peripheral nerve sheath tumors.
    Torres KE; Zhu QS; Bill K; Lopez G; Ghadimi MP; Xie X; Young ED; Liu J; Nguyen T; Bolshakov S; Belousov R; Wang S; Lahat G; Liu J; Hernandez B; Lazar AJ; Lev D
    Clin Cancer Res; 2011 Jun; 17(12):3943-55. PubMed ID: 21540237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.